Private capital juggernaut Blackstone has pressed play on a sale of CMAX, Australia’s longest-running provider of phase-1 clinical trials, in a deal that’s been on private equity firms’ radars since an ACCC undertaking last year.
CMAX has been offering phase-1 clinical trials since 1993.
Loading…